Overview

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Status:
Completed
Trial end date:
2021-02-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer